Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 18/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23700028 | 0.90 | PLAT (0.45) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL23700013 | 0.88 | PLAT (0.45) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL23700019 | 0.88 | PLAT (0.40) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL23699979 | 0.88 | PLAT (0.40) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL23699987 | 0.87 | PLAT (0.50) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL23700016 | 0.86 | PLAT (0.38) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL23198896 | 0.86 | PLAT (0.40) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL23700014 | 0.86 | PLAT (0.38) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL23700006 | 0.85 | PLAT (0.52) | PLATHSP90AA1GAAMAPTKMT2A | |
| SCHEMBL23198893 | 0.85 | PLAT (0.38) | PLATHSP90AA1GAAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112204029-B | Therapeutic compounds | 豪夫迈·罗氏有限公司 | 2024-03-01 | — | — | CN | claimed |
| US-20210238184-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2021-08-05 | — | — | US | claimed |
| CN-112204029-B | Therapeutic compounds | 豪夫迈·罗氏有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20210238184-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210238184-A1 | THERAPEUTIC COMPOUNDS | GENENTECH, INC. (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238184-A1 | THERAPEUTIC COMPOUNDS | YAP1, YES1, KRAS | PLAT 3945/4885HSP90AA1 461/4885GAA 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.